EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Feasibility Study of a Rapid Lateral Flow Immunoassay Test for Children and Adolescents to Determine SARS-CoV-2 Seroprevalence

Rukiye Saç iD, Medine Ayşin Taşar, Burcu Ceylan Cura Yayla iD, Serçin Taşar iD, Meliha Sevim, Gözde Onay, İlknur Fidancı

Viruses · 2025

DOI: 10.3390/v17121553 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, 2025. Verfasst von Rukiye Saç und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Ankara Training and Research Hospital, Ankara 06230, Turkey. Hauptthemen laut MEDLINE: Antibodies, Viral, COVID-19, SARS-CoV-2, COVID-19 Serological Testing. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Global seroprevalence of SARS-CoV-2 in children and adolescents has risen to an estimated 56.6%. Limited data on children highlights the need for ongoing surveillance as recommended by the WHO. Understanding this need, in this study we carry out a feasibility study of a rapid lateral flow immunoassay test (LFIAT) and determine SARS-CoV-2 seroprevalence in children and adolescents. The method used in the paper included 202 children (1–18 years old) who were evaluated for SARS-CoV-2 IgG/IgM antibodies using the LFIAT. LFIAT provides results in 20 min. Demographic data was collected through questionnaires. As a result, SARS-CoV-2 antibody seroprevalence was 52.0% (n = 105). No gender differences were observed. Adolescents exhibited higher seroprevalence (63.0%) compared to children aged 1–5.9 (49.3%) and 6–11.9 years old (46.8%), without statistical significance (p > 0.05). The median age of seropositive children was 9 years, and 77.1% had a history of PCR-confirmed infection (p = 0.001). In conclusion, results are consistent with global data. It was observed that the LFIAT can be easily administered to children and parents had a positive outlook on the test. Findings suggest that LFIAT can be used to assess SARS-CoV-2 immunity, while providing the first seroprevalence estimate for SARS-CoV-2 among healthy children and adolescents in Turkey, utilizing the COVID-19 IgG/IgM Rapid Test-KitA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, ViralCOVID-19SARS-CoV-2COVID-19 Serological TestingHumansChildAdolescentSeroepidemiologic StudiesMaleFemaleChild, PreschoolFeasibility StudiesImmunoglobulin GInfantImmunoassayImmunoglobulin M

Stichwörter der Autor:innen

SARS-CoV-2adolescentschildrenrapid lateral flow immunoassayseroprevalence

Substanzen

Antibodies, ViralImmunoglobulin GImmunoglobulin M

Autor:innen und Institutionen

  • Department of Pediatrics, Ankara Training and Research Hospital, Ankara 06230, Turkey.
  • Department of Pediatric Emergency, Ankara Training and Research Hospital, Ankara 06230, Turkey.
  • Department of Pediatric Infectious Diseases, Ankara Training and Research Hospital, Ankara 06230, Turkey.

ORCID-Profile: Rukiye Saç, Burcu Ceylan Cura Yayla, Serçin Taşar

Zitieren

APA

Saç, R., Taşar, M. A., Cura Yayla, B. C., Taşar, S., Sevim, M., Onay, G., & Fidancı, İ. (2025). A Feasibility Study of a Rapid Lateral Flow Immunoassay Test for Children and Adolescents to Determine SARS-CoV-2 Seroprevalence. Viruses. https://doi.org/10.3390/v17121553

Vancouver

Saç R, Taşar MA, Cura Yayla BC, Taşar S, Sevim M, Onay G, et al. A Feasibility Study of a Rapid Lateral Flow Immunoassay Test for Children and Adolescents to Determine SARS-CoV-2 Seroprevalence. Viruses. 2025. doi:10.3390/v17121553

BibTeX
@article{Sa2025,
  author = {Saç, Rukiye and Taşar, Medine Ayşin and Cura Yayla, Burcu Ceylan and Taşar, Serçin and Sevim, Meliha and Onay, Gözde and Fidancı, İlknur},
  title = {A Feasibility Study of a Rapid Lateral Flow Immunoassay Test for Children and Adolescents to Determine SARS-CoV-2 Seroprevalence},
  journal = {Viruses},
  year = {2025},
  doi = {10.3390/v17121553}
}
Kostenlos starten →